retinoblastoma management during the covid19 pandemic a report by the global retinoblastoma CORD-Papers-2022-06-02 (Version 1)

Title: Retinoblastoma management during the COVID19 pandemic: A report by the Global Retinoblastoma Study Group including 194 centers from 94 countries
Published: 2020-08-06
Journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.28584
Author Name: Fabian Ido Didi
Author link:
Author Name: Stacey Andrew W
Author link:
Author Name: Bowman Richard
Author link:
Author Name: Khetan Vikas
Author link:
Author Name: Blum Sharon
Author link:
Author Name: KerenFroim Naama
Author link:
Author Name: Staffieri Sandra
Author link:
Author Name: Foster Allen
Author link:
sha: 1b508c6b36e9102ead78cacdab3e3ca484df8a7c
license: no-cc
license_url: [no creative commons license associated]
source_x: Medline; PMC
pubmed_id: 32762025
pmcid: PMC7435529
has_full_text: TRUE
Keywords Extracted from Text Content: retinoblastoma patients retinoblastoma COVID-19
Extracted Text Content in Record: First 5000 Characters:). Table S1 shows the COVID-19 data per participating country during the study period, data on travel restrictions, and policy for retinoblastoma patients. In 51 countries (54.3%), there were fewer than 100 COVID-19-positive cases per average day; in 30 countries (31.9%), there were between 100 and 999 new positive cases; and in 9 (9.6%) countries, there were between 1000 and 10 000 new positive cases per day. In terms of deaths, no cases were reported in 23 (24.5%) of the participating countries; in 50 (53.2%) countries, there were 1 to 9 deaths per day on average; and in 17 (18.1%) countries; there were between 10 and 499 deaths per day on average. In Overall, 16 (8.3%) centers reported that retinoblastoma management was disrupted due to personnel being quarantined or sick (i.e., COVID-19 positive), 11 (5.7%) due to personnel being needed elsewhere, 7 (3.6%) due to equipment being needed elsewhere/missing, 40 (20.6%) due to a combination of factors, and 120 (61.9%) reported no disruption. We declare no competing interests relevant to the present work. Allen Foster 1 on behalf of the Global Retinoblastoma Study Group The complete list of authors is shown in the Supporting Information File. Ido Didi Fabian
Keywords Extracted from PMC Text: Staffieri REVISION Khetan Naama Keren‐Froim Sharon Blum
Extracted PMC Text Content in Record: First 5000 Characters:Ido Didi Fabian had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All the authors comply with ICMJE criteria for authorship. The authors are listed in alphabetical order. STUDY CONCEPT AND DESIGN Ido Didi Fabian. ACQUISITION, ANALYSIS OR INTERPRETATION OF DATA All coauthors. DRAFTING OF THE MANUSCRIPT Ido Didi Fabian, Andrew W. Stacey, Richard Bowman, Vikas Khetan, Sharon Blum, Naama Keren‐Froim, Sandra Staffieri, and Allen Foster. CRITICAL REVISION OF THE MANUSCRIPT FOR IMPORTANT INTELLECTUAL CONTENT All coauthors. All coauthors approved the final version for publication. We declare no competing interests relevant to the present work.
PDF JSON Files: document_parses/pdf_json/1b508c6b36e9102ead78cacdab3e3ca484df8a7c.json
PMC JSON Files: document_parses/pmc_json/PMC7435529.xml.json
G_ID: retinoblastoma_management_during_the_covid19_pandemic_a_report_by_the_global_retinoblastoma